February Supplemental Approvals
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Pfizer Pulls Celebrex's FAP Indication Quickly After Slow Trial Results
The European Medicines Agency issues a formal review, even though the claim had been withdrawn, in order to discourage off-label use.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.